Jardine-KY Reports April 2026 Monthly Revenue of NTD 180 Million (YoY +5.2%)
Key facts
- Jardine-KY Reports April 2026 Monthly Revenue of NTD 180 Million (YoY +5.2%)
- Jardine-KY has announced its monthly revenue for April 2026, reaching NTD 180 million, a year-on-year increase of 5.2%. This performance highlights the company's strong growth within the biotechnology and medical industry.
- Source: PR Times
- Date: April 1, 2026
Direct answer
Jardine-KY has announced its monthly revenue for April 2026, reaching NTD 180 million, a year-on-year increase of 5.2%. This performance highlights the company's strong growth within the biotechnology and medical industry.
- Citation
- Jardine-KY Reports April 2026 Monthly Revenue of NTD 180 Million (YoY +5.2%) (April 1, 2026), PR Times
- Source
- PR Times
- Date
- April 1, 2026
Jardine-KY has announced its monthly revenue for April 2026, reaching NTD 180 million, a year-on-year increase of 5.2%. This performance highlights the company's strong growth within the biotechnology and medical industry.
📋 Article Processing Timeline
- 📰 Published: April 1, 2026 at 09:00
- 🔍 Collected: May 13, 2026 at 08:00 (1007h 0m after Published)
- 🤖 AI Analyzed: May 13, 2026 at 08:31 (31 min after Collected)
Company Code: 4190
Company Name: Jardine-KY
Industry: Biotechnology and Medical Industry
Data Month: 2026-04
Monthly Revenue: NTD 179,900 thousand (NTD 180 million)
Year-on-year Change from Last Month: +5.2%
Company Name: Jardine-KY
Industry: Biotechnology and Medical Industry
Data Month: 2026-04
Monthly Revenue: NTD 179,900 thousand (NTD 180 million)
Year-on-year Change from Last Month: +5.2%
FAQ
What are the key facts in this article?
Jardine-KY has announced its monthly revenue for April 2026, reaching NTD 180 million, a year-on-year increase of 5.2%. This performance highlights the company's strong growth within the biotechnology and medical industry.
What is the direct answer?
Jardine-KY has announced its monthly revenue for April 2026, reaching NTD 180 million, a year-on-year increase of 5.2%. This performance highlights the company's strong growth within the biotechnology and medical industry.
What is the source and date?
PR Times: https://openapi.twse.com.tw/revenue/twse-rev-4190-11504 | April 1, 2026